Spots Global Cancer Trial Database for Gastroesophageal Varices in Cavernoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Gastroesophageal Varices in Cavernoma

Official Title: Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma

Study ID: NCT04525768

Conditions

Gastroesophageal Varices

Myeloproliferative Neoplasm

Portal Caver Cavernoma

Portal Hypertension

Interventions

JAK2 mutation test

Study Description

Brief Summary: Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.

Detailed Description: